Doubtful, they (FDA, and probably MSB) would want to see the data analysed for every measurable endpoint they can. So yes the primary endpoint is a simple binary response, are they alive or not, and this is the important one for this trial. But the secondary endpoints that can be recorded up to that 30 days will be looked at as well. It will take longer for the readout, but it's a good thing because the more measurable outcomes analysed, means more potential avenues for trials in future indications! More avenues, more revenues. Patience will pay off!
Links to why SI and FG said even if the interim readout shows overwhelming efficacy and Rem-L gets approved, MSB would prefer to continue doing the trial in its entirety, to gather the full data.
MSB Trading - 2020, page-18216
-
- There are more pages in this discussion • 4,945 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |